Novavax (NASDAQ: NVAX) started in 2020 as a micro cap. He was trading at $ 4 a share, and his market capitalization was barely over $ 100 million. The stock had fallen all the way to the ground with pennies. Biotechnics had no profit and no FDA approved medicine. Most investors had given up the shares. But there was reason to be bullish.
This small company had probably the best flu vaccine in the world, NanoFlu. The drug was in the middle of phase 3 trials, and it had won all of its head-to-head competitions against the market-leading flu vaccines by Sanofi (NASDAQ: sny). In March, when Novavax reported positive news in the Phase 3 trial for NanoFlu, shares rose to $ 14 a share.
This was a peach with three luggage in two months. What made this candidacy even more remarkable was the rest of the stock market was declining due to the coronavirus. Not surprisingly, Novavax had already announced that it was pursuing a COVID-19 vaccine. And the stock market loved the news.
Shares rose dramatically in May when the Coalition for Epidemic Preparation Innovation (CEPI) invested $ 384 million in the Novavax vaccine candidate for COVID-19. This was a major proof of Novavax science and sent stocks rising rapidly to $ 40 per share. In July, Novavax was awarded $ 1.6 billion by Operation Warp Speed to help pay for its COVID-19 vaccine. This news sent the shares over $ 100. And then the positive data from the Phase 1 trial sent shares over $ 180 per share. And this is how your stock goes above 4,000%.